Drug · DIN 02557347
TZIELD
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 20, 2025; first marketed August 20, 2025.
- Drug Identification Number (DIN)
- 02557347
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Teplizumab A10XX01
- Class
- Human
- Record last updated
- August 14, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| TEPLIZUMAB | 2 MG | 2 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 5, 2025: NOC 35295New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “tzield”. A notice may cover another product or only some lots: read it to see what it covers.
- TZIELD (teplizumab) and the Risk of Viral ReactivationSeptember 14, 2026 · Biologic or vaccine · New safety information - Adverse reaction - Product safety